Enhanced COMP catabolism detected in serum of patients with arthritis and animal disease models through a novel capture ELISA

Osteoarthritis and Cartilage

Volumn 20, Issue 8, 2012, Pages 854-862

  Lai, Y ^a,b   Yu, X P ^a   Zhang, Y ^b   Tian, Q ^b   Song, H ^b   Mucignat, M T ^c   Perris, R ^c   Samuels, J ^d   Krasnokutsky, S ^d   Attur, M ^d   Greenberg, J D ^d   Abramson, S B ^d   Di Cesare, P E ^e   Liu, C J ^b,f  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PARMA   (Italy)

^d NYU HOSPITAL FOR JOINT DISEASES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; COMP; Degradative fragments; ECM1; ELISA

Indexed keywords

ANTIRHEUMATIC AGENT; ATSTTRIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGENASE 3; ETANERCEPT; METHOTREXATE; PROGRANULIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRITIS; ARTICLE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOARTHRITIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS; TRANSGENIC ANIMAL;

ADOLESCENT; ADULT; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; MALE; METHOTREXATE; MICE; MICE, TRANSGENIC; MIDDLE AGED; OSTEOARTHRITIS; RECOMBINANT FUSION PROTEINS; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84862986533     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.05.003     Document Type: Article

References (39)

1. Huskisson E.C. Nimesulide, a balanced drug for the treatment of osteoarthritis. Clin Exp Rheumatol 2001, 19(1 Suppl 22):S21-S25.
2. Gouze J.N., Ghivizzani S.C., Gouze E., Palmer G.D., Betz O.B., Robbins P.D., et al. Gene therapy for rheumatoid arthritis. Hand Surg 2001, 6(2):211-219.
3. Campbell J.R. Nonfracture injuries to the canine elbow. J Am Vet Med Assoc 1969, 155(5):735-744.
4. Lukoschek M., Schaffler M.B., Burr D.B., Boyd R.D., Radin E.L. Synovial membrane and cartilage changes in experimental osteoarthrosis. J Orthop Res 1988, 6(4):475-492.
5. Mankin H.J. The response of articular cartilage to mechanical injury. J Bone Joint Surg Am 1982, 64(3):460-466.
6. DiCesare P., Hauser N., Lehman D., Pasumarti S., Paulsson M. Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon. FEBS Lett 1994, 354(2):237-240.
7. Hedbom E., Antonsson P., Hjerpe A., Aeschlimann D., Paulsson M., Rosa-Pimentel E., et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992, 267(9):6132-6136.
8. Di Cesare P.E., Carlson C.S., Stolerman E.S., Hauser N., Tulli H., Paulsson M. Increased degradation and altered tissue distribution of cartilage oligomeric matrix protein in human rheumatoid and osteoarthritic cartilage. J Orthop Res 1996, 14(6):946-955.
9. Neidhart M., Hauser N., Paulsson M., DiCesare P.E., Michel B.A., Hauselmann H.J. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 1997, 36(11):1151-1160.
10. Saxne T., Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992, 31(9):583-591.
11. Dickinson S.C., Vankemmelbeke M.N., Buttle D.J., Rosenberg K., Heinegard D., Hollander A.P. Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs. Matrix Biol 2003, 22(3):267-278.
12. Ganu V., Goldberg R., Peppard J., Rediske J., Melton R., Hu S.I., et al. Inhibition of interleukin-1alpha-induced cartilage oligomeric matrix protein degradation in bovine articular cartilage by matrix metalloproteinase inhibitors: potential role for matrix metalloproteinases in the generation of cartilage oligomeric matrix protein fragments in arthritic synovial fluid. Arthritis Rheum 1998, 41(12):2143-2151.
13. Stracke J.O., Fosang A.J., Last K., Mercuri F.A., Pendas A.M., Llano E., et al. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett 2000, 478(1-2):52-56.
14. Liu C.J., Kong W., Ilalov K., Yu S., Xu K., Prazak L., et al. ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J 2006, 20(7):988-990.
15. Liu C.J., Kong W., Xu K., Luan Y., Ilalov K., Sehgal B., et al. ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein. J Biol Chem 2006, 281(23):15800-15808.
16. Lohmander L.S., Saxne T., Heinegard D.K. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 1994, 53(1):8-13.
17. Petersson I.F., Boegard T., Svensson B., Heinegard D., Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998, 37(1):46-50.
18. Sharif M., Saxne T., Shepstone L., Kirwan J.R., Elson C.J., Heinegard D., et al. Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint. Br J Rheumatol 1995, 34(4):306-310.
19. Forslind K., Eberhardt K., Jonsson A., Saxne T. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 1992, 31(9):593-598.
20. Kraus V.B., Huebner J.L., Fink C., King J.B., Brown S., Vail T.P., et al. Urea as a passive transport marker for arthritis biomarker studies. Arthritis Rheum 2002, 46(2):420-427.
21. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29(8):1039-1049.
22. Kellgren J.H., Lawrence J.S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957, 16(4):494-502.
23. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324.
24. Fransen J., van Riel P.L. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009, 35(4):745-757. vii-viii.
25. Kong L., Tian Q., Guo F., Mucignat M.T., Perris R., Sercu S., et al. Interaction between cartilage oligomeric matrix protein and extracellular matrix protein 1 mediates endochondral bone growth. Matrix Biol 2010, 29(4):276-286.
26. DiCesare P.E., Morgelin M., Carlson C.S., Pasumarti S., Paulsson M. Cartilage oligomeric matrix protein: isolation and characterization from human articular cartilage. J Orthop Res 1995, 13(3):422-428.
27. DiCesare P.E., Morgelin M., Mann K., Paulsson M. Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding. Eur J Biochem 1994, 223(3):927-937.
28. Feldmann M., Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003, 9(10):1245-1250.
29. Deng G.M., Zheng L., Chan F.K., Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005, 11(10):1066-1072.
30. Li P., Schwarz E.M. The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003, 25(1):19-33.
31. Thwin M.M., Douni E., Aidinis V., Kollias G., Kodama K., Sato K., et al. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res Ther 2004, 6(3):R282-R294.
32. Tang W., Lu Y., Tian Q.Y., Zhang Y., Guo F.J., Liu G.Y., et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011, 332(6028):478-484.
33. Mansson B., Carey D., Alini M., Ionescu M., Rosenberg L.C., Poole A.R., et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995, 95(3):1071-1077.
34. Jordan J.M., Luta G., Stabler T., Renner J.B., Dragomir A.D., Vilim V., et al. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum 2003, 48(3):675-681.
35. Vilim V., Olejarova M., Machacek S., Gatterova J., Kraus V.B., Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 2002, 10(9):707-713.
36. Golightly Y.M., Marshall S.W., Kraus V.B., Renner J.B., Villaveces A., Casteel C., et al. Biomarkers of incident radiographic knee osteoarthritis: do they vary by chronic knee symptoms?. Arthritis Rheum 2011, 63(8):2276-2283.
37. Nurmohamed M.T., Dijkmans B.A. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005, 65(5):661-694.
38. Tiderius C.J., Sandin J., Svensson J., Dahlberg L.E., Jacobsson L. Knee cartilage quality assessed with dGEMRIC in rheumatoid arthritis patients before and after treatment with a TNF inhibitor. Acta Radiol 2010, 51(9):1034-1037.
39. Kawashiri S.Y., Kawakami A., Ueki Y., Imazato T., Iwamoto N., Fujikawa K., et al. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab. Joint Bone Spine 2010, 77(5):418-420.